Marker may help predict success with extended-wear contact lensesApril 04, 2017
April 4, 2017 - A simple marker on eye examination may help vision care professionals predict which patients will have a higher or lower rate of problems after starting extended-wear contact lenses, reports a study in the April issue of Optometry and Vision Science, the official journal of the American Academy of Optometry. The journal is published by Wolters Kluwer.
Over the long-term, deposits of the protein mucin on the eye surface might protect again inflammation and infection in patients using extended-wear contact lenses, suggests the new research by Loretta B. Szczotka-Flynn of University Hospitals Eye Institute, Cleveland, and colleagues.
Fewer Long-Term Problems with Extended-Wear Lenses in Patients with Mucin Deposits The researchers monitored short- and long-term responses to extended-wear contact lenses in 219 subjects. Made of oxygen-permeable silicon hydrogel materials, these relatively new products allow patients to wear their contact lenses continuously--including overnight--for up to 30 days.
During their first month with extended-wear lenses, nearly three-fourths of participants developed tiny deposits of mucin ("mucin balls") on the eye. Mucin is part of the mucus layer that helps to protect and lubricate the surface of the eye.
Nineteen percent of these subjects developed signs of possible inflammation/infection--called "corneal infiltrates"--compared to six percent of those without early mucin deposits. While corneal infiltrates are usually mild, they sometimes develop into serious infections.
Participants were then followed up during one year of extended-wear contact lens use. Once again, most subjects developed mucin deposits.
But this time, participants who developed mucin deposits were less likely to have problems. Rates of corneal infiltrates were 10.5 versus 14 percent for subjects with versus without "repeat" mucin deposits.
The larger the extent of repeat mucin deposits, the lower the risk of problems. Corneal infiltrates were more likely to develop in subjects wearing one of two types of silicone hydrogel contact lenses studied (comfilicon versus balafilicon).
The results question a recent study, which had suggested a lower risk of problems with mucin deposits developing under extended-wear contact lenses. Rather, patients with early mucin deposits appear to have a higher rate of corneal infiltrates, possibly reflecting a "disrupted mucus layer."
In the longer-term, mucin deposits may have a protective effect--"perhaps acting as a physical barrier between the lens and ocular surface once successful extended wear has been established." Dr. Szczotka-Flynn and colleagues conclude, "These findings are important for clinicians as they place and monitor their patients in extended wear."
-end-Click here to read "Mucin Balls Influence Corneal Infiltrative Events."
Article: "Mucin Balls Influence Corneal Infiltrative Events" (doi: 10.1097/OPX.0000000000001045)
About Optometry and Vision Science
Optometry and Vision Science, official journal of the American Academy of Optometry, is the most authoritative source for current developments in optometry, physiological optics, and vision science. This frequently cited monthly scientific journal has served primary eye care practitioners for more than 90 years, promoting vital interdisciplinary exchange among optometrists and vision scientists worldwide. Michael Twa, OD, PhD, FAAO, of University of Alabama-Birmingham School of Optometry is Editor-in-Chief of Optometry and Vision Science. The editorial office may be contacted at email@example.com
About the American Academy of Optometry
Founded in 1922, the American Academy of Optometry is committed to promoting the art and science of vision care through lifelong learning. All members of the Academy are dedicated to the highest standards of optometric practice through clinical care, education or research.
About Wolters Kluwer
Wolters Kluwer N.V. (AEX: WKL) is a global leader in information services and solutions for professionals in the health, tax and accounting, risk and compliance, finance and legal sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with specialized technology and services.
Wolters Kluwer reported 2016 annual revenues of €4.3 billion. The company, headquartered in Alphen aan den Rijn, the Netherlands, serves customers in over 180 countries, maintains operations in over 40 countries and employs 19,000 people worldwide.
Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).
For more information about our solutions and organization, visit http://www.wolterskluwer.com, follow us on Twitter, Facebook, LinkedIn, and YouTube.
Wolters Kluwer Health
Related Research Articles:
Related Research Reading: